Lilly Targets Dr. Reddy's Over Gemzar ANDA

Law360, New York (October 5, 2010, 5:42 PM EDT) -- Eli Lilly & Co. has accused generic-drug maker Dr. Reddy's Laboratories Ltd. of infringing a method patent for Gemzar in its attempt to launch a copycat version of the cancer treatment, on the heels of a federal appeals court decision that the asserted patent is invalid.

Lilly claims that Dr. Reddy's filing of an abbreviated new drug application for approval to manufacture a generic version of the drug infringes U.S. Patent Number 5,464,826, which was issued to Lilly in November 2005, according to a complaint filed...
To view the full article, register now.